Clinical Trials
3 trialsNCT03037385 2025-05-31
ARROW
Hoffmann-La Roche
Phase 1/2 Completed
NCT04760288 2024-01-05
AcceleRET-MTC
Hoffmann-La Roche
Phase 3 Withdrawn
NCT04204928 2021-08-13
Pre-Approval Access Program (PAAP) for Pralsetinib (BLU-667) in Patients With Unresectable or Metastatic NSCLC or MTC
Blueprint Medicines Corporation
Approved for marketing